| Patient | Ada Lovelace |
|---|---|
| Date of birth | 1990-12-10 |
| Identifiers | MRN HR-NI031-SYN; SSN (made up) 000-31-6729 |
| Document date | 2026-08-18 |
| Author | Constance Whitley-Adeyemi, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Mrs. Lovelace is a 35-year-old mathematician with stage IVB adenocarcinoma of the cervix, on carboplatin, paclitaxel and pembrolizumab, who comes for a preventive visit. She had her third cycle a week ago. There has been no bleeding since the pelvic radiation. Her average pelvic pain is about 3 of 10 on long-acting morphine 15 mg twice a day, with one or two breakthrough doses on some days, and she is not drowsy in the mornings. Her bowels open every day or two since the laxatives were increased. She has mild tingling in her toes. She is working on her mathematics most mornings. She would like her vaccinations brought up to date while she is on treatment, and to set down her wishes. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 35 |
| Treatment | Three cycles of carboplatin, paclitaxel and pembrolizumab |
| Pain | About 3 of 10 on long-acting morphine; no morning drowsiness |
| Bowels | Opening every day or two |
| Mood | PHQ-2 2 |
Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with her face to face by Dr. Whitley-Adeyemi. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Fair; better than in the spring |
| Psychosocial | Worried about her debts and about her family; supported at home |
| Tobacco | Never |
| Alcohol | None since diagnosis; AUDIT-C 0 |
| Gambling | Has stopped betting since her diagnosis; would like help with the debts |
| Physical activity | Short walks most days |
| Nutrition | Appetite fair; weight steady |
| Sleep | Seven hours, broken on the nights after chemotherapy |
| Safety | Feels safe at home; morphine kept in a locked box; naloxone at home |
| Sexual health | Not sexually active since the bleeding began |
| Activities of daily living | Independent |
| Hearing and vision | No concerns |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tiredness for a few days after each cycle; no fever or night sweats |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No mouth ulcers |
| Cardiovascular | Negative | No chest pain or leg swelling |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Bowels regular on laxatives; mild nausea for two days after each cycle |
| Genitourinary | Negative | No vaginal bleeding since radiation; light discharge; no urinary symptoms |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Positive | Hair thinning on chemotherapy; no rash |
| Neurological | Positive | Mild tingling in the toes, not affecting walking |
| Endocrine | Negative | No heat or cold intolerance |
| Psychiatric | Negative | Mood fair; PHQ-2 score 2 |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain | 0.5 mL four to six times a day as needed | Oral route | 2024-06-03 to 2026-06-02 | completed | S |
| Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain | 5 mg every 4 hours as needed | Oral route | 2026-06-02 | active | S |
| Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole | every 12 hours | Oral route | 2026-06-16 to 2026-10-20 | completed | S |
| Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 | one spray as needed for suspected overdose; repeat after 2 to 3 minutes if needed | Nasal route | 2026-06-02 | active | S |
| Senna 8.6 mg tablet, two tablets by mouth at night | two tablets at night | Oral route | 2026-06-02 | active | S |
| Polyethylene glycol 3350, 17 g in water by mouth once or twice a day | once daily, up to twice daily | Oral route | 2026-06-02 | active | S |
| Acetaminophen 500 mg tablet, two tablets by mouth three times a day | 1 g three times a day | Oral route | 2026-06-02 | active | S |
| Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits | 750 mg on two occasions two weeks apart | Intravenous route | 2026-06-02 to 2026-06-17 | completed | S |
| Pembrolizumab 200 mg intravenously every 3 weeks | every 3 weeks | Intravenous route | 2026-06-30 | active | S |
| Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles | every 3 weeks for six cycles | Intravenous route | 2026-06-30 to 2026-10-13 | completed | S |
| Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication | every 3 weeks for six cycles | Intravenous route | 2026-06-30 to 2026-10-13 | completed | S |
| Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed | twice a day for three days after each cycle, then as needed | Oral route | 2026-06-30 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-18 | Body height | 165 | cm | S |
| 2026-08-18 | Body weight | 53.6 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 80 | /min | S |
| 2026-08-18 | Respiratory rate | 16 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-18 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 2 | {score} | S |
Vital signs recorded on 2026-08-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Slender, alert; weight 53.6 kg, BMI 19.7; blood pressure 110/70, pulse 80 |
| Mouth | No mucositis or thrush |
| Neck | No thyroid enlargement; no lymph node enlargement |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft; mild suprapubic tenderness; no masses |
| Skin | Diffuse hair thinning; no rash |
| Neurological | Light touch slightly reduced at the toes; vibration normal; gait normal |
| Psychiatric | Engaged and humorous; not sedated |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intake | resolved | confirmed | N93.8 | S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairs | active | confirmed | D50.0 | S — Synthetic modern finding anchored to her documented final illness. |
| Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 2018 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosis | active | confirmed | C53.0 | S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice. |
| Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extension | active | confirmed | G89.3 | S — Synthetic modern diagnosis made at the second visit. |
| Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone supplied | active | confirmed | Z79.891 | S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing. |
| Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxatives | resolved | confirmed | K59.03 | S — Synthetic adverse drug effect; not a historical claim. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure | Completed today | 110/70 mmHg |
| Depression screening | Completed today | PHQ-2 score 2; PHQ-9 9 five weeks ago |
| Tobacco use | Completed today | Never used tobacco |
| Unhealthy alcohol use | Completed today | AUDIT-C 0; no alcohol since diagnosis |
| Intimate partner violence screening | Completed today | Screened in private; negative |
| HIV screening | Up to date | Nonreactive at diagnosis |
| Hepatitis C screening | Up to date | Antibody nonreactive at diagnosis |
| Hepatitis B screening and vaccination | Completed today | Surface antigen, core antibody and surface antibody all negative before treatment; CpG-adjuvanted vaccine dose 1 of 2 today |
| Pneumococcal vaccine | Completed today | PCV20 today for an immunocompromising condition |
| Zoster vaccine | Completed today | Recombinant zoster vaccine dose 1 of 2 today, recommended from 19 for immunocompromised adults |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap today |
| Influenza vaccine | Due | Inactivated vaccine in the autumn, between cycles |
| COVID-19 vaccine | Due | Current vaccine in the autumn; recommended for immunocompromised adults |
| HPV vaccine | Not indicated | Age 35 and already diagnosed with an HPV-related cancer |
| Live vaccines | Not indicated | Contraindicated during chemotherapy and immunotherapy |
| Cervical cancer screening | Not indicated | Under treatment for cervical cancer |
| Breast cancer screening | Not indicated | Not due before 40 at average risk |
| Diabetes and lipid screening | Not indicated | Not a priority during treatment; BMI 19.7 |
| Contraception and pregnancy | Completed today | Not sexually active; told that chemotherapy and pembrolizumab can harm a pregnancy and to use contraception if that changes |
Immunizations given today: Pneumococcal conjugate vaccine (PCV20); Recombinant zoster vaccine, dose 1 of 2; Tdap vaccine; Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 1 of 2 [S]
Guideline basis: Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Fourteen-week review in three weeks, after the restaging CT. Next scheduled visit 2026-09-08: fourteen-week review: restaging CT, blood counts, iron and thyroid, pain, and a goals-of-care conversation. [S]
Voluntary advance care planning discussion of about 30 minutes, with her consent, in the context of metastatic cancer. She named a health care agent and an alternate, recorded in the chart and not named here, and completed a health care proxy form. She wants treatment aimed at living longer while it lets her think and work, wants to be told the truth about her illness directly, and does not want her life prolonged by machines if she could no longer think clearly. Her wishes on resuscitation will be revisited after the restaging scan. A copy was sent to her oncology and palliative care teams. [S]